A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer
-
Cancer -
Lung Cancer -
Non-Small Cell Lung Cancer (NSCLC)
For the latest version of this information please go to www.forpatients.roche.com